IL259919A - Interleukin-15 compositions and uses thereof - Google Patents
Interleukin-15 compositions and uses thereofInfo
- Publication number
- IL259919A IL259919A IL259919A IL25991918A IL259919A IL 259919 A IL259919 A IL 259919A IL 259919 A IL259919 A IL 259919A IL 25991918 A IL25991918 A IL 25991918A IL 259919 A IL259919 A IL 259919A
- Authority
- IL
- Israel
- Prior art keywords
- interleukin
- compositions
- Prior art date
Links
- 102000003812 Interleukin-15 Human genes 0.000 title 1
- 108090000172 Interleukin-15 Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562270447P | 2015-12-21 | 2015-12-21 | |
| PCT/US2016/067042 WO2017112528A2 (en) | 2015-12-21 | 2016-12-15 | Interleukin-15 compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL259919A true IL259919A (en) | 2018-07-31 |
Family
ID=59091160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL259919A IL259919A (en) | 2015-12-21 | 2018-06-10 | Interleukin-15 compositions and uses thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180360977A1 (enExample) |
| EP (1) | EP3393486A4 (enExample) |
| JP (1) | JP2019503348A (enExample) |
| KR (1) | KR20180089516A (enExample) |
| CN (1) | CN108472324A (enExample) |
| AU (1) | AU2016378387A1 (enExample) |
| BR (1) | BR112018012262A2 (enExample) |
| CA (1) | CA3007819A1 (enExample) |
| IL (1) | IL259919A (enExample) |
| MX (1) | MX2018007304A (enExample) |
| WO (1) | WO2017112528A2 (enExample) |
| ZA (1) | ZA201803875B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3639845B1 (en) * | 2017-07-25 | 2023-06-21 | Jiangsu Hengrui Medicine Co., Ltd. | Il-15 protein complex pharmaceutical composition and uses thereof |
| TWI834636B (zh) * | 2018-02-26 | 2024-03-11 | 美商欣爍克斯公司 | Il-15結合物及其用途 |
| CN112533629A (zh) | 2018-06-19 | 2021-03-19 | 阿尔莫生物科技股份有限公司 | 结合使用il-10药剂与嵌合抗原受体细胞疗法的组合物和方法 |
| JP7611136B2 (ja) * | 2018-11-09 | 2025-01-09 | ネクター セラピューティクス | 別の薬理学的に活性な薬剤と組み合わせた長時間作用型インターロイキン－１５受容体作動薬 |
| SG11202111175YA (en) * | 2019-04-26 | 2021-11-29 | Prolynx Llc | Slow-release cytokine conjugates |
| US20220241375A1 (en) | 2019-05-20 | 2022-08-04 | Cytune Pharma | Il-2/il-15r beta gamma agonist dosing regimens for treating cancer or infectious diseases |
| WO2021030688A1 (en) * | 2019-08-15 | 2021-02-18 | Igm Biosciences, Inc. | Immunostimulatory multimeric binding molecules |
| CN114555632A (zh) * | 2019-08-23 | 2022-05-27 | 新索思股份有限公司 | Il-15缀合物及其用途 |
| MX2023004880A (es) | 2020-10-26 | 2023-05-11 | Cytune Pharma | AGONISTA DE IL-2/IL-15RßY PARA EL TRATAMIENTO DE CÁNCER DE PIEL QUE NO ES MELANOMA. |
| AU2021367887A1 (en) | 2020-10-26 | 2023-06-01 | Cytune Pharma | IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA |
| BR112023027305A2 (pt) | 2021-06-23 | 2024-03-12 | Cytune Pharma | Variante de interleucina-15, conjugado, proteína de fusão, ácido nucleico, vetor, célula hospedeira e composição farmacêutica |
| KR20240043797A (ko) | 2021-08-13 | 2024-04-03 | 싸이튠 파마 | 암 치료용 IL-2/IL-15Rβγ 작용제와 항체-약물 접합체 조합 |
| CN118251495A (zh) * | 2021-11-26 | 2024-06-25 | 杰科（天津）生物医药有限公司 | 一种蛋白的生产方法及其应用 |
| US20250082777A1 (en) | 2022-01-10 | 2025-03-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20250222027A1 (en) | 2022-04-01 | 2025-07-10 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| CN117510828A (zh) * | 2022-07-28 | 2024-02-06 | 厦门赛诺邦格生物科技股份有限公司 | 一种含氨基酸残基的三臂聚乙二醇衍生物 |
| WO2024215989A1 (en) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS |
| WO2024215987A1 (en) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE516305T1 (de) * | 2004-02-27 | 2011-07-15 | Inst Nat Sante Rech Med | Il-15-bindungsstelle für il-15-ralpha und spezifische il-15-mutanten mit wirkung als agonisten/antagonisten |
| AR050693A1 (es) * | 2004-08-11 | 2006-11-15 | Zheng Xin Xiao | Composiciones que contienen interleuquina-15 mutante y supresion de una respuesta inmune. |
| JP2008515896A (ja) * | 2004-10-05 | 2008-05-15 | オクスナー クリニック ファウンデーション | Ｉｌ−１５によるｂ細胞増殖の増強 |
| MA39711A (fr) * | 2014-04-03 | 2015-10-08 | Nektar Therapeutics | Conjugués d'une fraction d'il-15 et d'un polymère |
| MX2017004838A (es) * | 2014-10-14 | 2017-10-16 | Armo Biosciences Inc | Composiciones de interleucina-15 y usos de estas. |
-
2016
- 2016-12-15 CN CN201680079249.3A patent/CN108472324A/zh active Pending
- 2016-12-15 BR BR112018012262A patent/BR112018012262A2/pt not_active Application Discontinuation
- 2016-12-15 US US16/060,389 patent/US20180360977A1/en not_active Abandoned
- 2016-12-15 KR KR1020187020534A patent/KR20180089516A/ko not_active Withdrawn
- 2016-12-15 AU AU2016378387A patent/AU2016378387A1/en not_active Abandoned
- 2016-12-15 JP JP2018530797A patent/JP2019503348A/ja not_active Withdrawn
- 2016-12-15 CA CA3007819A patent/CA3007819A1/en not_active Abandoned
- 2016-12-15 MX MX2018007304A patent/MX2018007304A/es unknown
- 2016-12-15 EP EP16879902.1A patent/EP3393486A4/en not_active Withdrawn
- 2016-12-15 WO PCT/US2016/067042 patent/WO2017112528A2/en not_active Ceased
-
2018
- 2018-06-10 IL IL259919A patent/IL259919A/en unknown
- 2018-06-11 ZA ZA2018/03875A patent/ZA201803875B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN108472324A (zh) | 2018-08-31 |
| MX2018007304A (es) | 2019-03-14 |
| WO2017112528A2 (en) | 2017-06-29 |
| JP2019503348A (ja) | 2019-02-07 |
| EP3393486A4 (en) | 2019-09-11 |
| ZA201803875B (en) | 2019-08-28 |
| BR112018012262A2 (pt) | 2018-12-04 |
| KR20180089516A (ko) | 2018-08-08 |
| AU2016378387A1 (en) | 2018-07-05 |
| EP3393486A2 (en) | 2018-10-31 |
| WO2017112528A3 (en) | 2017-08-31 |
| CA3007819A1 (en) | 2017-06-29 |
| US20180360977A1 (en) | 2018-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201803875B (en) | Interleukin-15 compositions and uses thereof | |
| ZA201702213B (en) | Interleukin-15 compositions and uses thereof | |
| GB2546350B (en) | Compositions and methods | |
| HUE065174T2 (hu) | HLA-alapú módszerek és készítmények, valamint azok felhasználása | |
| IL250568A0 (en) | Anti-methanogenic preparations and their uses | |
| ZA201803451B (en) | Probiotic compositions and uses thereof | |
| SG11201707876YA (en) | Microalgal compositions and uses thereof | |
| GB201519187D0 (en) | Improved binder compositions and uses thereof | |
| GB201718876D0 (en) | Antithrombin-heparin compositions and methods | |
| GB201519188D0 (en) | Improved binder compositions and uses thereof | |
| GB201706352D0 (en) | Methods compositions and uses relating thereto | |
| GB201706355D0 (en) | Methods compositions and uses relating thereto | |
| GB201502002D0 (en) | Uses and compositions | |
| GB201706356D0 (en) | Methods compositions and uses relating thereto | |
| GB201608762D0 (en) | Compositions and uses thereof | |
| GB201715785D0 (en) | Methods compositions and uses relating thereto | |
| GB2550632B (en) | Compositions and uses and methods relating thereto | |
| GB201715820D0 (en) | Compositions and methods | |
| GB201705626D0 (en) | Compositions and methods | |
| GB201502026D0 (en) | Uses and compositions | |
| GB201501991D0 (en) | Uses and compositions | |
| GB201512996D0 (en) | Compositions and methods | |
| ZA201807665B (en) | Methods and compositions | |
| GB201614897D0 (en) | Compositions and uses thereof | |
| IL248863A0 (en) | Preparations containing il-31 and their use |